Cantor Fitzgerald Forecasts Weaker Earnings for Precigen

Key Points

• Cantor Fitzgerald has revised its FY2026 earnings estimate for Precigen to $0.07 per share, down from $0.11, while maintaining an "Overweight" rating on the stock.
• Precigen recently reported $0.86 million in revenue for the quarter, exceeding analyst estimates, and had a negative net margin of 2,868.66%.
• Several research firms have upgraded their ratings and price targets for Precigen, with JMP Securities raising its target from $6.00 to $8.00.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Cantor Fitzgerald reduced their FY2026 earnings per share (EPS) estimates for Precigen in a report released on Tuesday, August 19th. Cantor Fitzgerald analyst J. Kim now anticipates that the biotechnology company will post earnings of $0.07 per share for the year, down from their previous forecast of $0.11. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

Precigen (NASDAQ:PGEN - Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. The company had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.67 million.

PGEN has been the topic of several other reports. Citigroup reissued an "outperform" rating on shares of Precigen in a report on Tuesday. Wall Street Zen upgraded Precigen from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. JMP Securities boosted their price target on Precigen from $6.00 to $8.00 and gave the stock a "market outperform" rating in a research report on Tuesday. HC Wainwright restated a "buy" rating and set a $8.50 price objective on shares of Precigen in a research note on Tuesday. Finally, JPMorgan Chase & Co. upgraded shares of Precigen from an "underweight" rating to a "neutral" rating in a report on Friday, August 15th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $8.25.

Precigen Trading Up 14.8%

Shares of PGEN traded up $0.54 during mid-day trading on Wednesday, hitting $4.18. The company's stock had a trading volume of 24,184,755 shares, compared to its average volume of 14,296,194. The company's 50-day moving average is $1.87 and its 200-day moving average is $1.67. Precigen has a 52-week low of $0.65 and a 52-week high of $4.21. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -9.95 and a beta of 1.87.

Institutional Investors Weigh In On Precigen

Several institutional investors have recently added to or reduced their stakes in PGEN. Parkman Healthcare Partners LLC acquired a new stake in Precigen in the 1st quarter worth approximately $4,755,000. Bank of America Corp DE raised its holdings in shares of Precigen by 258.2% in the second quarter. Bank of America Corp DE now owns 832,261 shares of the biotechnology company's stock worth $1,182,000 after buying an additional 599,914 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Precigen by 3.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company's stock worth $16,801,000 after buying an additional 410,595 shares during the period. Marshall Wace LLP acquired a new stake in shares of Precigen during the second quarter worth $524,000. Finally, Diametric Capital LP purchased a new stake in shares of Precigen during the second quarter valued at $476,000. Institutional investors and hedge funds own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.